The Impact of Type 2 Diabetes Mellitus on Hepatic Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study
GE - Portuguese Journal of Gastroenterology · 02.03.2026 · 33 (1) · 413-421
DOI: 10.1159/000551207 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift GE - Portuguese Journal of Gastroenterology, online erschienen am 02.03.2026. Verfasst von Paula Mesquita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Local Health Unit of the Aveiro Region, Aveiro, Portugal. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The aim of the study was to evaluate the impact of type 2 diabetes on hepatic fibrosis in patients with MASLD. Materials and Methods: This cross-sectional study used retrospective data from patients with MASLD who underwent liver elastography between July 2022 and February 2024. Controlled attenuation parameter ≥248 dB/m was considered diagnostic for steatosis; elasticity (kPa) of 8.7–10.2 kPa for F3, and >10.2 kPa for F4. Clinical, demographic, and laboratory data were collected. Other etiologies of liver disease were excluded. Patients were divided into group 1 (with diabetes) and group 2 (without diabetes).
Results
A total of 252 individuals were included, 96 in group 1 and 156 in group 2. The mean age was 56 years, and the median body mass index was 31.0 kg/m2. There was a positive correlation between the degree of steatosis and the stage of fibrosis (p < 0.01). The prevalence of steatosis S3 was 83.3% in group 1 versus 70.5% in group 2 (p = 0.022). Fibrosis F3/F4 was present in 45.8% of group 1 compared to 12.2% of group 2 (p < 0.001), while presumed cirrhosis affected 33.3% of group 1 and 6.4% of group 2 (p < 0.001).
Conclusions
Type 2 diabetes was associated with a higher degree of steatosis and more severe hepatic fibrosis in patients with MASLD, with presumed cirrhosis present in about one-third of patients with diabetes. Early diagnosis of MASLD in type 2 diabetes and screening for complications (cirrhosis and hepatocellular carcinoma) should be implemented.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Department, Local Health Unit of the Aveiro Region, Aveiro, Portugal.
- Liver Disease Functional Unit - Internal Medicine Department, Local Health Unit of Coimbra, Coimbra, Portugal.
- School of Technology and Management, Polytechnic Institute of Viseu, Viseu, Portugal.
- Research Centre in Digital Services (CISeD), Viseu, Portugal.
- Centre for Mathematics of the University of Coimbra (CMUC), Coimbra, Portugal.
- Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Zitieren
APA
Mesquita, P., Macedo, C., Matos, A., Henriques, C., Carvalho, A., & Simão, A. (2026). The Impact of Type 2 Diabetes Mellitus on Hepatic Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study. GE - Portuguese Journal of Gastroenterology, 33(1), 413-421. https://doi.org/10.1159/000551207
Vancouver
Mesquita P, Macedo C, Matos A, Henriques C, Carvalho A, Simão A. The Impact of Type 2 Diabetes Mellitus on Hepatic Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study. GE - Portuguese Journal of Gastroenterology. 2026;33(1):413-421. doi:10.1159/000551207
BibTeX
@article{Mesquita2026,
author = {Mesquita, Paula and Macedo, Cristiane and Matos, Ana and Henriques, Carla and Carvalho, Armando and Simão, Adélia},
title = {The Impact of Type 2 Diabetes Mellitus on Hepatic Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study},
journal = {GE - Portuguese Journal of Gastroenterology},
year = {2026},
volume = {33},
number = {1},
pages = {413--421},
doi = {10.1159/000551207}
}
EUVIMED